Precision(TM) Plus Spinal Cord Stimulator System Receives CE Mark Approval For Peripheral Nerve Stimulation

Date: Aug-29-2012Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its
PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System, the world's first rechargeable SCS
device, in peripheral nerve stimulation for patients with chronic intractable pain of the
trunk. Peripheral nerve stimulation provides physicians and patients with an additional
treatment option for managing chronic intractable pain of the trunk by stimulating
peripheral nerves through a small surgically implantable device.

"I am pleased to learn the PRECISION PLUS SCS System has received CE Mark approval for
peripheral nerve stimulation," said Dr. David Abejón, consultant anaesthetist at Hospital
Universitario Puerta de Hierro Majadahonda, Madrid. "Based on my clinical experience and
research with peripheral nerve stimulation therapy to date, this technique seems to be a
promising treatment option in the field of chronic intractable pain management."

Chronic intractable pain is continuous pain has lasted more than six months. Living in
constant pain for an extended period time can have a devastating impact to quality of life
for many patients. Without relief, or the hope for relief, many patients lose the ability
to sleep, work, and function normally.

"Chronic pain affects nearly 95 million adults throughout Europe," said Michael
Onuscheck, senior vice president and president of Europe, Middle East and Africa at Boston
Scientific. "Expanding our neuromodulation portfolio to include peripheral nerve
stimulation with the PRECISION PLUS SCS System continues our commitment to providing
physicians and patients with multiple treatment options for the management of this
debilitating condition."

About the PRECISION PLUSSCS System

The PRECISION PLUS SCS System was approved in the United States in 2004 and received
approval in Europe and Canada in 2005. The system is the world's first rechargeable
implantable pulse generator. Today, more than 60,000 patients worldwide have been treated
using this system. When compared to non-rechargeable SCS systems, rechargeable SCS systems
may offer clinical benefits by extending therapeutic longevity and therefore avoiding
frequent replacement surgeries and complications that may arise from repeated surgeries.

All cited trademarks are the property of their respective owners. Caution: The law
restricts these devices to sale by or on the order of a physician. Inactions,
contraindications, warnings, and instructions for use can be found on the product labeling
supplied with each device. Information is for use only in countries with applicable health
authority product registrations.

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.